Insider · CIK 0001333277
Paul T Quinlan
Files at ORKA (Oruka Therapeutics, Inc.). First filing Mar 17, 2026, latest Sep 21, 2026.
Paul T Quinlan files SEC Form 4 as officer at ORKA (Oruka Therapeutics, Inc.). Since Mar 17, 2026, Paul T Quinlan has reported 0 open-market buys worth $0 and 4 open-market sells worth $1.1M, the latest filed on Sep 21, 2026.
A track record needs three past buys with six months of prices behind them; Paul T Quinlan has 0, so none is measured yet.
The newest scored trade: sold $936k of ORKA on Sep 21, 2026, filed Sep 21, 2026, scored 29 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 4 sells worth $1.1M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ORKA: Oruka Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 29Weak | Oruka Therapeutics, Inc. | $936k 10,000 shares | -25% | +520% from low-17% from high | |
| 40Moderate | Oruka Therapeutics, Inc. | $99k 1,039 shares | -3% | - | |
| 37Weak | Oruka Therapeutics, Inc. | $51k 733 shares | -2% | +532% from low-10% from high | |
| 35Weak | Oruka Therapeutics, Inc. | $30k 733 shares | -2% | +516% from low0% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 14, 2026 | ORKA Oruka Therapeutics, Inc. | 71,000 0.11% of outstanding | $7.7M | Aug 14, 2026 | $51k |
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 21, 2026 | ORKA Oruka Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +10,000 | $7.80 | $78k | 39,995 | 22 d ago |
| Sep 21, 2026 | ORKA Oruka Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -2,900 | $92.37 | $268k | 37,095 | 22 d ago |
| Sep 21, 2026 | ORKA Oruka Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -3,832 | $93.32 | $358k | 33,263 | 22 d ago |
| Sep 21, 2026 | ORKA Oruka Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -601 | $94.44 | $57k | 32,662 | 22 d ago |
| Sep 21, 2026 | ORKA Oruka Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -2,667 | $95.31 | $254k | 29,995 | 22 d ago |
| Sep 21, 2026 | ORKA Oruka Therapeutics, Inc. | MOption exercise Employee Warrant (right to buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 79,996 | 22 d ago |
| Sep 15, 2026 | ORKA Oruka Therapeutics, Inc. | SOpen-market sale Common Stock | -1,039 | $95.71 | $99k | 29,995 | 28 d ago |
| Jun 15, 2026 | ORKA Oruka Therapeutics, Inc. | SOpen-market sale Common Stock | -733 | $69.69 | $51k | 31,034 | Jun 15, 2026 |
| Mar 16, 2026 | ORKA Oruka Therapeutics, Inc. | SOpen-market sale Common Stock | -733 | $41.30 | $30k | 31,767 | Mar 17, 2026 |
| Jan 23, 2026 | ORKA Oruka Therapeutics, Inc. | AGrant or award Common Stock | +32,500 | $0.00 | $0 | 32,500 | Jan 23, 2026 |
| Jan 23, 2026 | ORKA Oruka Therapeutics, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +130,000 | $0.00 | $0 | 130,000 | Jan 23, 2026 |
Questions about Paul T Quinlan
Answered from the filings on this page, as of the latest one.
Is Paul T Quinlan buying or selling?
In the last 12 months Paul T Quinlan reported 0 open-market buys worth $0 and 4 open-market sells worth $1.1M on SEC Form 4; the latest was sold $936k of ORKA on Sep 21, 2026. Grants, option exercises and tax withholding are not counted.
How did Paul T Quinlan's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Paul T Quinlan has 0.
Where does Paul T Quinlan file Form 4?
Paul T Quinlan has filed Form 4 at ORKA (Oruka Therapeutics, Inc.) as General Counsel. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.